Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
| Autor: | Steed MB; Department of Oral and Maxillofacial Surgery, Medical University of South Carolina, Room BSB 453 MSC 507, 173 Ashley Avenue, Charleston, SC 29425, USA. Electronic address: steedma@musc.edu., Swanson MT; Department of Oral and Maxillofacial Surgery, Medical University of South Carolina, Room BSB 453 MSC 507, 173 Ashley Avenue, Charleston, SC 29425, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Oral and maxillofacial surgery clinics of North America [Oral Maxillofac Surg Clin North Am] 2016 Nov; Vol. 28 (4), pp. 515-521. Date of Electronic Publication: 2016 Sep 10. |
| DOI: | 10.1016/j.coms.2016.06.011 |
| Abstrakt: | The new direct oral anticoagulants-dabigatran etexilate, rivaroxaban, and apixaban- have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many surgeons are wary of these drugs, as there is limited evidence on how to manage bleeding in patients taking them, and only recently has a specific antidote been developed to reverse their anticoagulant effect. Management of the newer agents requires careful adherence to primary measures of bleeding care, knowledge of their mechanism of action, and familiarity with the unapproved and untested reversal strategies that may be required in patients with life-threatening bleeding. (Copyright © 2016 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|